Stephen E Rose

Title: Innovations in Drug Delivery: The Contributions of Stephen E. Rose

Introduction

Stephen E. Rose is an accomplished inventor based in Flushing, MI (US). He has made significant contributions to the field of drug delivery through his innovative work on liposomal nanoparticles. His research focuses on enhancing the therapeutic efficacy of retinoids, particularly fenretinide, in treating various diseases.

Latest Patents

Stephen E. Rose holds a patent for "Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery." This patent describes formulations of neutral retinoids, specifically fenretinide (HPR), in the form of lipid nanoparticles, solid dispersions, and emulsions. These compositions are designed to treat diseases that can benefit from HPR, such as neoplastic diseases, by achieving higher and more prolonged concentrations of HPR in patients. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, and optional lyophilization for long-term stable storage. Importantly, these formulations are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses, as they avoid chemical surfactants and animal sources of phospholipids in their manufacture.

Career Highlights

Stephen E. Rose is associated with Scitech Development, LLC, where he continues to advance his research in drug delivery systems. His work has the potential to significantly impact the treatment of various diseases, making it a vital area of study in the pharmaceutical field.

Collaborations

Stephen has collaborated with notable colleagues, including Ralph E. Parchment and Bhaskara Rao Jasti. Their combined expertise contributes to the innovative approaches in drug formulation and delivery.

Conclusion

Stephen E. Rose's contributions to the field of drug delivery through his patent on liposomal nanoparticles exemplify the importance of innovation in medical therapies. His work not only enhances the efficacy of treatments but also prioritizes patient safety.